Background-Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43% and death or first hospitalization for heart failure (HF) by 37% in the African-American Heart Failure Trial (A-HeFT). Reduction in mortality makes it difficult to determine the effect on hospitalizations unless the analysis adjusts for death as a competing risk.
D espite considerable improvements in the clinical management of patients with heart failure (HF), hospitalization rates remain high with enormous costs to the healthcare system. 1, 2 HF accounts for 1% to 2% of the total healthcare expenditure, and these costs are increasing. 3, 4 
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Analyses of hospital admissions of patients with symptomatic HF are complicated by the competing risk of deaths that preclude admissions. [5] [6] [7] Hence, the relationship between hospitalizations and mortality needs to be taken into account when analyzing the effects of a treatment for HF on hospitalizations especially when the treatment has an effect on the mortality rate. A composite end point of time to first hospitalization or death is often used to simplify the analysis of clinical trials. However, the effect of the treatment on hospital admissions is not clear if the treatment affects mortality.
Focusing on only the first admission may not represent the treatment's effect on the overall burden of admissions. The risks of death and recurrent admissions are increased after hospital discharge. 2, 8 Few studies have reported the effect of HF therapies on all hospitalizations including recurrences. The randomized cardiac resynchronization trials Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) 5 and Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) 9 were the first HF trials to report a reduction in all hospitalizations for HF using appropriate statistical methods that account for the competing risk of death and correlation of repeated admissions in the same patient. More recently, the SHIFT (Systolic Heart September 2014
Failure Treatment with the I f inhibitor Ivabradine Trial) 6 and the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) 7 trials found that the pure heart rate-slowing agent ivabradine and the mineralocorticoid receptor antagonist eplerenone reduced all HF hospitalizations.
Recently, there has been great interest in reducing all-cause readmissions that occur <30 days after a hospitalization for worsening HF. 10, 11 These data are used to determine Medicare payments to hospitals for inpatient HF care, and hospitals with above average readmission rates are being financially penalized. 1 Whether 30-day readmission rates can be reduced by therapy is unclear, and most clinical trials have not reported the effects of treatments on 30-day all-cause readmission rates. Public measures of 30-day readmission rates count all readmissions, not only those for HF. However, most 30-day readmissions are not because of worsening HF and may not be responsive to treatments for HF. 10, 12 We used several statistical methods that take into account the effects of the competing risk of death and correlation of recurrent admissions of a patient to estimate the effect of the fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) on (1) first hospitalizations only, (2) all hospitalizations including recurrences, and (3) the 30-day all-cause readmission rates in subjects who were discharged alive from their first hospitalization for HF in the African-American Heart Failure Trial (A-HeFT). 13, 14 
Methods

Study Design and Patient Selection
The details of A-HeFT have previously been published. 13, 14 Briefly, A-HeFT was a randomized, placebo-controlled, double-blind trial of FDC-I/H versus placebo in 1050 self-identified black patients with New York Heart Association class III to IV systolic HF receiving standard-of-care HF therapy in the United States. Randomization to either FDC-I/H or a placebo added to background therapy was stratified according to baseline use of a β-blocker. An independent central committee adjudicated the cause of all deaths and hospitalizations. 13 The study was approved by the institutional review board at each center, and all subjects provided written informed consent.
Data Analysis
Cumulative mortality curves were estimated as 1 minus the Kaplan-Meier survival curves that were compared using the log-rank test.
Hospitalization Analyses With Death as a Competing Risk
The Fine-Gray competing risks regression model was used to estimate hazard ratios (HRs) and cumulative incidence (proportion) curves for first hospitalizations for HF and separately for any cause, with death as a competing risk for hospitalization. 15 For the analysis of all hospitalizations including recurrences, we jointly fit regression models of the hazards of hospitalizations and death including a random subject effect (frailty) to account for correlation between repeated admissions in the same person and death. 16 Separate analyses were done for all hospitalizations for HF and all causes.
30-Day Readmission Rates
The baseline characteristics of the subjects with first hospitalization for HF in each treatment group were compared using the 2-sample t test for means of continuous measures and Pearson χ 2 test for proportions. Cox regression analysis was used to compare the 30-day allcause readmission rates in subjects who were discharged alive from their first hospitalization for HF in the FDC-I/H and placebo groups.
Adjustment was made for baseline differences in patient characteristics. There were too few 30-day readmissions for HF (15 in placebo group and 8 in FDC-I/H group) to do a HF-specific analysis.
Stata Statistical Software release 12 (StataCorp, College Station, TX) was used for all analyses except the joint frailty models that were estimated using the R package, frailtypack. 17 A P value <0.05 was considered significant without adjustment for making multiple comparisons for this secondary analysis of data from a clinical trial.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the article as written.
Results
Mortality
A total of 1050 self-identified black patients were randomized in A-HeFT: 518 to FDC-I/H and 532 to placebo group. During a median follow-up of 450 days (interquartile range, 227-541), 86 (8.2%) patients died. The cumulative mortality shown in Figure 1 was significantly lower (HR, 0.57; 95% confidence interval [CI], 0.37-0.89; P=0.013) in the FDC-I/H group. However, there were only small differences between the mortality curves earlier during the trial when most hospital admissions occurred.
Hospitalizations
The number of all-cause and HF admissions is summarized in Table 1 . There were 558 all-cause and 251 HF hospitalizations in placebo compared with 435 and 173 hospitalizations in the FDC-I/H groups, respectively. Most of the all-cause hospitalizations in the placebo group were recurrences (337 of 558; 60%) as were the hospitalizations for HF (155 of 251; 62%). Thus, the effect of FDC-I/H on recurrent hospitalizations could have a substantial influence on the analyses of all hospitalizations. Hospitalizations for HF, which are the ones most likely to be amenable to treatment with FDC-I/H, were 43% (96 of 221) of first hospitalizations, 46% (155 of 337) of recurrent hospitalizations, and 45% (251 of 558) of all admissions in the placebo group.
Estimated Effects of FDC-I/H on First Hospitalizations
The reduction in mortality in the FDC-I/H group may have increased the risk of hospitalization compared with the placebo 
Estimated Effects of FDC-I/H on All Hospitalizations
Effect of FDC-I/H on 30-Day All-Cause Readmissions
There were 214 subjects who had at least 1 admission for HF and were discharged alive. Nine subjects were lost to follow-up <30 days of discharge (5 in placebo and 4 in FDC-I/H group) and 1 patient died the day after being discharged. The remaining 204 subjects were included in the analysis of 30-day all-cause readmissions. The baseline characteristics of these patients, by treatment group, are shown in Table 2 and Table II Figure 2 ) in these much smaller subgroups of subjects, although the HR appeared to be lower (HR, 0.59) than that for the first (HR, 0.88) or all recurrent hospitalizations for any cause (HR, 0.75). Adjusting for differences in baseline characteristics of those who were admitted for HF shown in Table 2 did not change the estimate substantially (HR, 0.61; 95% CI, 0.30-1.23; P=0.17).
Discussion
The primary analysis of A-HeFT showed that the addition of FDC-I/H to guideline-based background therapy, including β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aldosterone blockers, significantly reduced all-cause mortality, the composite end point of first HF hospitalization or deaths (HR, 0.63), and improved the subjects' quality of life. 14, 18 The present analysis of the first HF hospitalizations that considered deaths as a competing event found a similar effect of FDC-I/H (HR, 0.61). With little difference in mortality during the first 300 days of follow-up when many of the first admissions for HF occurred, this finding is not unexpected. Had FDC-I/H reduced mortality early on, the estimated effect on first hospital admissions may have been different in a competing risk analysis. The previously published observations from A-HeFT that FDC-I/H was associated with significant left ventricular reverse remodeling and decrease in natriuretic peptide <6 months 19 also suggests an early beneficial effect of the drug combination on myocardial structure. This analysis confirmed that recurrent hospitalizations are common in patients with HF (57% of the total in this study during a median follow-up of 450 days). 2 Despite concerns that recurring hospitalizations for HF that accounted for the majority of all hospitalizations for HF may not be responsive to continued treatment, the effect of FDC-I/H was still evident when recurrent HF hospitalizations were included in the analysis (HR, 0.66). Taking the relationship with deaths that were more common in the placebo group into account when analyzing all hospitalizations for HF may have increased the estimated effect of FDC-I/H. However, we cannot rule out the possibility that changes in HF treatments or differences in patients' risk at discharge contributed to the estimated effect of FDC-I/H. Interestingly, a significant beneficial effect was observed when total all-cause hospitalizations were analyzed rather than only the first all-cause hospitalization. This may be explained by the effect of FDC-I/H on all (recurrent) other cardiovascular non-HF hospitalizations that were also reduced by the drug but not significantly (HR, 0.81; 95% CI, 0.65-1.01; P=0.06).
Heart Failure Hospitalizations
The 30-day all-cause readmission rate after first HF hospitalization, which is being used as a hospital performance measure, was similar in the placebo group (23%) to that reported in the Medicare database (24.8%) 10, 11 and tended to be lowered by FDC-I/H (14.8%). However, the A-HeFT database was not sufficient to detect an effect of FDC-I/H on this outcome. The number of first admissions for HF was relatively small (n=215), and only 41 patients (29 in placebo and 12 in FDC-I/H group) had a readmission <30 days. Analysis of 30-day readmissions after all recurrent HF rather than only the first HF admissions could increase the numbers, but may add to the difficulty of estimating an adjusted treatment effect in these subgroups that are not randomly assigned to treatment at each discharge. Hence, this was not attempted. If 30-day all-cause readmissions continue to be used as a hospital performance measure, randomized controlled trials of treatments begun during the hospital stay or shortly thereafter need to be performed to control for differences in surviving patients' characteristics, including all treatments.
Patients with chronic HF are at increased risk of the related outcomes of death and hospitalization. Although the Figure 3 . Cumulative incidence curves for the first all-cause and first heart failure hospitalizations by treatment group. The Fine-Gray competing risks regression model was used to estimate the hazard ratio (HR) and cumulative incidence curves with deaths as the competing risk for hospitalization. Notice how the curves for the first heart failure hospitalizations begin to separate early when there was no difference in mortality, whereas the curves for first all-cause hospitalizations do not begin to separate until later. CI indicates confidence interval; and FDC-I/H, fixed-dose combination of isosorbide dinitrate and hydralazine. appropriate use of neurohormonal blockade and more recently of defibrillator and cardiac resynchronization devices has improved the overall prognosis of patients with HF, hospitalizations for worsening HF remain the most common cause of admission in the elders. 20, 21 Moreover, HF hospitalizations are often recurrent, distressing to the patient, expensive, and are associated with increased subsequent mortality. 8 A reduction in HF hospitalizations may reduce subsequent hospitalizations and death and contribute to the reduction of the total burden to the patient and society. The early reduction in hospitalizations for HF in A-HeFT may have contributed to the later differences in mortality and HF readmissions. However, patients with HF typically have many comorbidities, some of which cause hospitalizations that may not respond to treatments for HF. Moreover, patients with recurrent admissions for HF may be refractory and not amenable to continued treatment. Therefore, the effects of treatments on first and all hospitalizations for HF rather than just the first admissions for HF should be examined. Moreover, the inclusion of recurrent hospitalizations in the primary end point of a clinical trial may help to reduce the sample size if the treatment has a similar effect on the recurrent admissions as on the first, because recurrences increase the incident rate. Some studies are being designed to include recurrences in an effort to reduce the sample size and make it more informative. For example, when we used the current data and a formula for a negative binomial regression model of hospitalizations (that ignores competing risk) to estimate the number needed to have 90% power to detect a 25% reduction in the hospitalization rate, a study of total all-cause hospitalizations would require 1454 total subjects, whereas counting only first allcause hospitalizations would require 2066 subjects to detect the same difference.
In conclusion, the effect of a treatment for HF on the highly distressing and expensive hospitalizations is important. In this study, several secondary analyses consistently indicated that the use of FDC-I/H can substantially reduce the commonly occurring hospitalizations for HF and thereby the total number and burden of hospitalizations.
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